# Vaxart Biosciences Inc.

Canonical: https://abierto.us/vendors/vaxart-biosciences-inc-ws6umd1qtbc9

- UEI: WS6UMD1QTBC9
- CAGE: 4GQK7
- Location: South San Francisco, CA
- Awards in window: 1 (4 transactions), $9,271,191 obligated, January 12, 2024 to February 2, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $9,271,191

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $9,271,191

## Competition

- Full and Open Competition: 1 awards

## Solicitations won

- Oral Mucosal Vaccine for SARS-CoV2 Protection (75A50124C00002), $9,271,193. https://abierto.us/opportunities/75a50124c00002

## Largest awards

- 75A50124C00002 (definitive contract): $9,271,191, Barda - Aspr / Daappo / Barda DCMA. Clinical Trial Planning Activities for a Phase 2B Clinical Trial That Compares Vaxart'S XBB Vaccine Candidate to an Mrna Comparator to Evaluate Efficacy for Symptomatic and Asymptomatic Disease, Systemic and Mucosal Immune Induction, and Adverse. https://www.usaspending.gov/award/CONT_AWD_75A50124C00002_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/vaxart-biosciences-inc-ws6umd1qtbc9.